Injectable Devices for Biological Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Injection Devices for Biological Drugs Market is segmented By Type of product (Glass material, Plastic material), By Site of administration (Skin, Circulatory/Musculoskeletal System, Organs, Central Nervous System), By Usability (Reusable Pen Injectors, Disposable Pen Injectors), By Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Aesthetic Treatment, Other clinical applications), By End-user (Hospitals and Clinics, Home Care Settings, Others), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Injection Devices for Biological Drugs Market size is expected to grow at a high CAGR during the forecast period (2024-2031).   Injection devices for biological drugs refer to devices used for administering biological drugs, such as proteins, antibodies and vaccines, into the body through injections.

They include syringes, auto-injectors and pen injectors. These devices help to ensure accurate dosing and make the administration process more convenient and efficient.

Injectable Devices for Biological Drugs Market Summary

For More Insights Request Free Sample

Injection Devices for Biological Drugs Market Dynamics

The global injection devices for biological drugs market growth is driven by an increase in demand for biological drugs, growing prevalence of chronic diseases, advancements in drug delivery technology, growing geriatric population, increase in investment in r&d of injectable devices, increase in regulatory approvals for biological drugs, growth in the biopharmaceutical industry and rise in adoption of self-injection devices.

The Increasing Government Support for Research and Development in Pharma and Medical Devices Drives the Market Growth 

The increasing government support for research and development in pharma and medical devices and technological advancements drive the market worldwide. In October 2021, the government released a draft policy for R&D, Pharma and Medical Devices. The policy focuses on simplifying regulatory processes to enable rapid drug discovery, development and innovation in medical devices, exploring mechanisms to incentivize private sector investment in research and evaluating various funding mechanisms, including budgetary support, venture capital, CSR funding and fiscal incentives to support innovation; and strengthening the R&D ecosystem through increased collaboration between industry and academia to develop mechanisms to dovetail research as per the requirement of the industry. 

In addition, the market players are applying market strategies such as product launches and collaboration to expand their business. For instance, in August 2022, West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.

The Drawbacks Associated with Injection Devices for Biological Drugs will Hamper the Growth of the Market

However, some of the drawbacks or restraining factors of the injection devices for the biological drugs market. These devices are often expensive, making it difficult for patients to afford them. Some injection devices require specialized training for proper use, which may only be readily available to some healthcare providers. There needs to be more standardization in design and compatibility across different devices, which can lead to confusion and errors in dosing. 

Some injection devices are complex and difficult to use, which can lead to user error and decreased patient satisfaction. Reimbursement policies for these devices vary by country and region, affecting the overall market growth. Some biological drugs require specific storage and handling conditions, which can be difficult to maintain in certain settings.

COVID-19 Impact on Injection Devices for Biological Drugs Market

The COVID-19 pandemic has had positive effects on injection devices for biological drugs. The increasing prevalence of chronic diseases is leading to a rise in the overall use of syringes, particularly disposable syringes. Chronic disease products already on the market are expected to be largely unaffected by COVID-19. This includes insulin delivery devices, rheumatoid therapeutics delivery devices and well-established cancer therapies. Consequently, the rise in the incidence of chronic diseases is expected to continue to drive market growth.

Catalent Biologics has observed steady autoinjector demand from its customers since the pandemic's start. This is possible because the patients typically administer autoinjector products in-home. Patients using autoinjectors do not need to leave their homes to receive healthcare, which is helpful when trying social distancing during the pandemic.

Injection Devices for Biological Drugs Market Segmentation Analysis

The Glass Material Segment is Expected to Grow at the Fastest CAGR During the Forecast Period (2024-2031)  

The glass material segment accounts for the highest market share. Pharmaceutical companies provide simple, pen-like insulin injectors for treating diabetes to new levels in devices using DuPont Delrin acetal and Zytel nylon resin as the injector pen materials. Durability is key for Autopen. It can dispense up to 72 units per injection and is designed to be refilled with a new insulin cartridge and used repeatedly.  

In the United States, children may get over 13 vaccine injections by age 16. Unfortunately, various problems are associated with the hypodermic needles used for these injections. One of the most significant drawbacks is the cost of the relatively high needles—the cost results in a lower vaccination rate, especially for children in developing countries.

Needle-free systems are designed to solve these problems making them safer, less expensive and more convenient. It is anticipated that these systems will increase the incidence of vaccination and reduce the number of prescribed antibiotics. Moreover, they should reduce the number of needle stick accidents that have resulted in some healthcare workers contracting diseases.

Source: DataM Intelligence Analysis (2023)

Global Injection Devices for Biological Drugs Market Geographical Share

North America Region Holds the Largest Market Share of the Global Injection Devices for Biological Drugs Market 

North America dominates the market for injection devices for biological drugs and is expected to show a similar trend over the forecast period. Technological advancements, the rising prevalence of chronic disease and product launches by market players in the North American region drive the market. Technological advancements in self-administration, coupled with the rise of biologics in the pharmaceutical market, are some other factors that propel the market's growth. 

The market players are offering injection devices in the North American region. For instance, BD offers commercialized platforms, such as glass or plastic prefilled syringes (BD Neopak, BD Sterifill Advance), BD UltraSafe passive needle guard, BD Vystra disposable pen, BD Physioject and BD Intevia 1mL autoinjectors or products in development, such as BD Intevia 2.25mL, BD Libertas wearable injector and BD Evolve on-body injector, their customers can start own development choosing from platform technologies that support a broad design space (volume, viscosity and usage). Customers can narrow their selections over time within those options, as trade-offs require balancing formulations, volumes, drug-container compatibility and ergonomics.

Source: DataM Intelligence Analysis (2023)

Injection Devices for Biological Drugs Companies and Competitive Landscape

The injection devices for the biological drugs market are a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, ELI Lilly and Company, Sandoz (Novartis AG), Terumo Corporation, Teva Pharmaceutical Industries Ltd. and Crossject, among others. 

The major players are adopting several growth strategies, such as product launches, acquisitions and collaborations, contributing to the growth of injection devices for the biological drug market globally. 

For instance,

• In May 2022, The international technology group SCHOTT expanded its production capacity of ready-to-use (RTU) cartridges. This drug containment and delivery solution is used to store and administer drugs with the help of pen injectors or wearable devices.

Becton, Dickinson and Company

Overview: 

BD provides a differentiated solution and a complete portfolio of self-injection systems developed for the patient and developed with a modular platform technology that enables it to customize products rapidly and aims to accelerate its time to market. The company provides the flexible manufacturing, customization, drug compatibility and seamless integration that combination products require today to succeed. 

Product Portfolio:

BD Libertas: A novel injection method named the BD Libertas Wearable Injector was created to deliver complicated biologics with viscosities as high as 50 cP in 2-5 mL and 5-10 mL configurations, either at home or in a clinical setting. The mechanical spring-based power source of the BD Libertas Wearable Injector eliminates the need for batteries or heavy metals disposal concerns.

The Global Injection Devices for Biological Drugs Market Report Would Provide Access to Approximately 40+ Market Data Tables, 45+ Figures and a Range of 200 (approximate) Pages.